Alpelisib in the Treatment of Metastatic HR+ Breast Cancer with PIK3CA Mutations

References

• Bray F , FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Mariotto AB , EtzioniR, HurlbertM, PenberthyL, MayerM. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol. Biomarkers Prev.26(6), 809–815 (2017).
   PubMed Web of Science ®Google Scholar
• Cardoso F , CostaA, SenkusE, AaproM, AndreF, BarriosCH3rd. ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann. Oncol.28, 16–33 (2017).
   PubMed Web of Science ®Google Scholar
• Wesolowski R , RamaswamyB. Gene expression profiling: changing face of breast cancer classification and management. Gene Expr.15, 105–115 (2011).
   PubMed Web of Science ®Google Scholar
• Lobbezoo DJA , van KampenRJW, VoogdAC, DercksenMW, vanden Berkmortel F, SmildeTJ. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res. Treat.141, 507–514 (2013).
   PubMed Web of Science ®Google Scholar
• Schiff R ,FuquaSA. Clinical aspects of estrogen and progesterone receptors. In: Diseases of the Breast, 4th Edition . HarrisJR, LippmanME, OsborneCK, MorrowM(Eds). Wolters Kluwer/ Lippincott Williams & Wilkins, PA, USA, 408–430 (2009).
   Google Scholar
• Caswell-Jin JL , PlevritisSK, TianL, CadhamCJ, XuC, StoutNK. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr.2(4), pky062 (2018).
   PubMedGoogle Scholar
• Cole MP , JonesCTA, ToddIDH. A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI46474. Br. J. Cancer25(2), 270–275 (1971).
   PubMed Web of Science ®Google Scholar
• Buzdar AU , JonatW, HowellA, JonesSE, BlomqvistCP, VogelCL. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials. Arimidex Study Group. Cancer83(6), 1142–1152 (1998).
   PubMed Web of Science ®Google Scholar
• Dombernowsky P , SmithI, FalksonG, LeonardR, PanasciL, BellmuntJ. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol.16(2), 453–461 (1998).
   PubMed Web of Science ®Google Scholar
• Kaufmann M , BajettaE, DirixLY, FeinLE, JonesSE, ZilemboN. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. The Exemestane Study Group. J. Clin. Oncol.18(7), 1399–1411 (2000).
   PubMed Web of Science ®Google Scholar
• Di Leo A , JerusalemG, PetruzelkaL, TorresR, BondarenkoIN, KhasanovR. Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J. Clin. Oncol.28(30), 4594–4600 (2010).
   PubMed Web of Science ®Google Scholar
• Robertson JFR , BondarenkoIM, TrishkinaE, DvorkinM, PanasciL, ManikhasA. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, Phase III trial. Lancet388(10063), 2997–3005 (2016).
   PubMed Web of Science ®Google Scholar
• Mouridsen H , GershanovichM, SunY, Pérez-CarriónR, BoniC, MonnierA. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol.19(10), 2596–2606 (2001).
   PubMed Web of Science ®Google Scholar
• Bonneterre J , BuzdarA, NabholtzJM, RobertsonJF, ThürlimannB, von EulerM. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer92(9), 2247–2258 (2001).
   PubMed Web of Science ®Google Scholar
• Paridaens RJ , DirixLY, BeexLV, NooijM, CameronDA, CuferT. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J. Clin. Oncol.26(30), 4883–4890 (2008).
   PubMed Web of Science ®Google Scholar
• Baselga J , CamponeM, PiccartM, BurrisHA, RugoHS, SahmoudT. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med.366, 520–529 (2012).
   PubMed Web of Science ®Google Scholar
• Bachelot T , BourgierC, CropetC, Ray-CoquardI, FerreroJM, FreyerG. Randomized Phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol.30(22), 2718–2724 (2012).
   PubMed Web of Science ®Google Scholar
• Kornblum N , ZhaoF, ManolaJ, KleinP, RamaswamyB, BrufskyA. Randomized Phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J. Clin. Oncol.36(16), 1556–1563 (2018).
   PubMed Web of Science ®Google Scholar
• Wolff AC , LazarAA, BondarenkoI, GarinAM, BrincatS, ChowL. Randomized Phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J. Clin. Oncol.31(2), 195–202 (2013).
   PubMed Web of Science ®Google Scholar
• Schmid P , ZaissM, Harper-WynneC, FerreiraM, DubeyS, ChanS. Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor–positive metastatic breast cancer. The MANTA Phase II randomized clinical trial. JAMA Oncol.5(11), 1556–1563 (2019).
   PubMed Web of Science ®Google Scholar
• Slamon DJ , NevenP, ChiaS, FaschingPA, DeLaurentiis M, ImS. Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients with hormone receptor positive (HR +), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Ann. Oncol.30(Suppl. 5), v851–v934 (2019).
   Google Scholar
• Im S-A , LuY-S, BardiaA, HarbeckN, ColleoniM, FrankeF. Overall survival with ribociclib plus endocrine therapy in breast cancer. N. Engl. J. Med.381, 307–316 (2019).
   PubMed Web of Science ®Google Scholar
• Sledge GW Jr , ToiM, NevenP, SohnJ, InoueK, PivotX. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy – MONARCH 2, a randomized clinical trial. AMA Oncol.6(1), 116–124 (2020).
   Web of Science ®Google Scholar
• Johnston S , MartinM, DiLeo A, ImSA, AwadaA, ForresterT. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer5, 5 (2019).
   PubMed Web of Science ®Google Scholar
• Finn RS , MartinM, RugoHS, JonesS, ImS-A, GelmonK. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med.375, 1925–1936 (2016).
   PubMed Web of Science ®Google Scholar
• Turner NC , SlamonDJ, RoJ, BondarenkoI, ImS-A, MasudaN. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med.379, 1926–1936 (2018).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN , StemmerSM, BurrisHA, YapY-S, SonkeGS, Paluch-ShimonS. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N. Engl. J. Med.375, 1738–1748 (2016).
   PubMed Web of Science ®Google Scholar
• O’Leary B , CuttsRJ, LiuY, HrebienS, HuangX, FenwickK. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov.8(11), 1390–1403 (2018).
   PubMed Web of Science ®Google Scholar
• Osborne CK , SchiffR. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med.62, 233–247 (2011).
   PubMed Web of Science ®Google Scholar
• Klinge CM . Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res.29(14), 2905–2919 (2001).
   PubMed Web of Science ®Google Scholar
• Kushner PJ , AgardDA, GreeneGL, ScanlanTS, ShiauAK, UhtRM. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol.74(5), 311–317 (2000).
   PubMed Web of Science ®Google Scholar
• Toy W , ShenY, WonH, GreenB, SakrRA, WillM. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet.45(12), 1439–1445 (2013).
   PubMed Web of Science ®Google Scholar
• Robinson DR , WuYM, VatsP, SuF, LonigroRJ, CaoX. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet.45(12), 1446–1451 (2013).
   PubMed Web of Science ®Google Scholar
• Schiavon G , HrebienS, Garcia-MurillasI, CuttsRJ, PearsonA, TarazonaN. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci. Transl. Med.7(313), 313ra182 (2015).
   PubMed Web of Science ®Google Scholar
• Fribbens C , O’LearyB, KilburnL, HrebienS, Garcia-MurillasI, BeaneyM. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J. Clin. Oncol.34(25), 2961–2968 (2016).
   PubMed Web of Science ®Google Scholar
• Jeselsohn R , YelenskyR, BuchwalterG, FramptonG, Meric-BernstamF, Gonzalez-AnguloAM. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer. Clin. Cancer Res.20(7), 1757–1767 (2014).
   PubMed Web of Science ®Google Scholar
• Jeselsohn R , BuchwalterG, DeAngelis C, BrownM, SchiffR. ESR1 mutations as a mechanism for acquired endocrine resistance in breast cancer. Nat. Rev. Clin. Oncol.12(10), 573–583 (2015).
   PubMed Web of Science ®Google Scholar
• Herrera-Abreu MT , PalafoxM, AsgharU, RivasMA, CuttsRJ, Garcia-MurillasI. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res.76(8), 2301–2313 (2016).
   PubMed Web of Science ®Google Scholar
• Caldon CE , MusgroveEA. Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div.5, 2 (2010).
   PubMed Web of Science ®Google Scholar
• Turner NC , LiuY, ZhuZ, LoiS, ColleoniM, LoiblS. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor–positive metastatic breast cancer. J. Clin. Oncol.37, 1169–1178 (2019).
   PubMed Web of Science ®Google Scholar
• Finn RS , CrownJP, LangI, BoerK, BondarenkoIM, KulykSO. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised Phase II study. Lancet16(1), 25–35 (2015).
   Web of Science ®Google Scholar
• Schiff R , MassarwehSA, ShouJ, BharwaniL, MohsinSK, OsborneCK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res.10(1), 331–336 (2004).
   PubMed Web of Science ®Google Scholar
• Lee AV , CuiX, OesterreichS. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin. Cancer Res.7, 4429–4435 (2001).
   PubMed Web of Science ®Google Scholar
• Nicholson RI , HutchesonIR, HiscoxSE, KnowldenJM, GilesM, BarrowD. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr. Relat. Cancer12(Suppl. 1), 29–36 (2005).
   Google Scholar
• Vasan N , ToskaE, ScaltritiM. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann. Oncol.30(Suppl. 10), x3–x11 (2019).
   PubMedGoogle Scholar
• Zardavas D , PhillipsWA, LoiS. PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res.16, 201 (2014).
   PubMed Web of Science ®Google Scholar
• Vivanco I , SawyersCL. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nat. Rev. Cancer2, 489–501 (2002).
   PubMed Web of Science ®Google Scholar
• Katso R , OkkenhaugK, AhmadiK, WhiteS, TimmsJ, WaterfieldMD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol.17, 615–675 (2001).
   PubMed Web of Science ®Google Scholar
• Engelman JA , LuoJ, CantleyLC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet.7(8), 606–619 (2006).
   PubMed Web of Science ®Google Scholar
• Chagpar RB , LinksPH, PastorMC, FurberLA, HawryshAD, ChamberlainMD. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc. Natl Acad. Sci. USA107(12), 5471–5476 (2010).
   PubMed Web of Science ®Google Scholar
• Corvera S , CzechMP. Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol.8(11), 442–446 (1998).
   PubMed Web of Science ®Google Scholar
• Van der Haar E , LeeSI, BandhakaviS, GriffinTJ, KimDH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol.9(3), 316–323 (2007).
   PubMed Web of Science ®Google Scholar
• Cantley LC , NeelBG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA96(8), 4240–4245 (1999).
   PubMed Web of Science ®Google Scholar
• Campbell RA , Bhat-NakshatriP, PatelNM, ConstantinidouD, AliS, NakshatriH. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α. J. Biol. Chem.276(13), 9817–9824 (2001).
   PubMed Web of Science ®Google Scholar
• Miller TW , HennessyBT, Gonzalez-ArguloAM, FoxEM, MillsGB, ChenH. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Invest.120(7), 2406–2413 (2010).
   PubMed Web of Science ®Google Scholar
• Crowder RJ , PhommalyC, TaoY, HoogJ, LuoJ, PerouCM. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor positive breast cancer. Cancer Res.69(9), 3955–3962 (2009).
   PubMed Web of Science ®Google Scholar
• Bosch A , LiZ, BergamaschiA, EllisH, ToskaE, PratA. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci. Transl. Med.7(283), 283ra51 (2015).
   PubMed Web of Science ®Google Scholar
• Toska E , OsmanbeyogluHU, CastelP, ChanC, HendricksonRC, ElkabetsM. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science355(6331), 1324–1330 (2017).
   PubMed Web of Science ®Google Scholar
• Samuels Y , VelculescuVE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle3(10), e17–e19 (2004).
   Web of Science ®Google Scholar
• Karakas B , BachmannKE, ParkBH. Mutation of the PIK3CA oncogene in human cancers. Br. J. Cancer94, 455–459 (2006).
   PubMed Web of Science ®Google Scholar
• Campbell IG , RussellSE, ChoongDYH, MontgomeryKG, CiaravellaML, HooiCSF. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res.64, 7678–7681 (2004).
   PubMed Web of Science ®Google Scholar
• Samuels Y , WangZ, BardelliA, SillimanN, PtakJ, SzaboS. High frequency of mutations of the PIK3CA gene in human cancers. Science304, 554 (2004).
   PubMed Web of Science ®Google Scholar
• Bachmann KE , ArganiP, SamuelsY, SillimanN, PtakJ, SzaboS. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther.3, 772–775 (2004).
   PubMed Web of Science ®Google Scholar
• Miller TW , RexerBN, GarrettJT, ArteagaCL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res.13, 224 (2011).
   PubMed Web of Science ®Google Scholar
• Saal LH , HolmK, MaurerM, MemeoL, SuT, WangX. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res.65, 2554–2559 (2005).
   PubMed Web of Science ®Google Scholar
• Lehmann BD , BauerJA, SchaferJM, PendletonCS, TangL, JohnsonKC. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res.16(4), 406 (2014).
   PubMed Web of Science ®Google Scholar
• Burke JE , PerisicO, MassonGR, VadasO, WilliamsRL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110 α (PIK3CA). PNAS109(38), 15259–15264 (2012).
   PubMed Web of Science ®Google Scholar
• Perez-Tenorio G , AlkhoriL, OlssonB, WalterssonMA, NordenskjöldB, RutqvistLE. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res.13(12), 3577–3584 (2007).
   PubMed Web of Science ®Google Scholar
• Rudolph M , AnzenederT, SchulzA, BeckmannG, ByrneAT, JeffersM. AKT1E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer16, 622 (2016).
   PubMed Web of Science ®Google Scholar
• Miron A , VaradiM, CarrascoD, LiH, LuongoL, KimHJ. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res.70(14), 5674–5678 (2010).
   PubMed Web of Science ®Google Scholar
• Dunlap J , LeC, ShuklaA, PattersonJ, PresnellA, HeinrichMC. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res. Treat.120(2), 409–418 (2010).
   PubMed Web of Science ®Google Scholar
• Isakoff SJ , EngelmannJA, IrieHY, BrachmannSM, PearlineRV, CantleyLC. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res.65(23), 10992–11000 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao JJ , LiuZ, WangL, ShinE, LodaMF, RobertsTM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl Acad. Sci. USA102(51), 18443–18448 (2005).
   PubMed Web of Science ®Google Scholar
• Kalinsky K , JacksLM, HeguyA, PatilS, DrobnjakM, UmeshkumarK. PIK3CA mutation associates with improved outcome in breast cancer. Clin. Cancer Res.15(16), 5049–5059 (2009).
   PubMed Web of Science ®Google Scholar
• Cizkova M , SusiniA, VacherS, Cizeron-ClairacG, AndrieuC, DriouchK. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res.14, R28 (2012).
   PubMed Web of Science ®Google Scholar
• Ellis MJ , LinL, CrowderR, TaoY, HoogJ, SniderJ. Phosphatidyl-inositol-3-kinase aplha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res. Treat.119(2), 379–390 (2010).
   PubMed Web of Science ®Google Scholar
• Lopez-Knowles E , SegalCV, GaoQ, Garcia-MurillasI, TurnerNC, SmithI. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. Breast Cancer Res.16, R68 (2014).
   PubMed Web of Science ®Google Scholar
• Sabine VS , CrozierC, BrookesCL, DrakeC, PiperT, vande Velde CJH. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J. Clin. Oncol.32(27), 2951–2959 (2014).
   PubMed Web of Science ®Google Scholar
• Beelen K , OpdamM, SeversonTM, KoornstraRHT, VincentAD, WesselingJ. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Res.16, R13 (2014).
   PubMed Web of Science ®Google Scholar
• Loi S , MichielsS, LambrechtsD, FumagalliD, ClaesB, Kellokumpu-LehtinenP-L. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. JNCI105(13), 960–967 (2013).
   PubMedGoogle Scholar
• Stemke-Hale K , Gonzalez-AnguloAM, LluchA, NeveRM, KuoW-L, DaviesM. An integrative genomic and proteomic analysis of PIK3CA PTEN and AKT mutations in breast cancer. Cancer Res.68(15), 6084–6091 (2008).
   PubMed Web of Science ®Google Scholar
• Pang B , ChengS, SunS-P, AnC, LiuZ-Y, FengX. Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis. Sci. Rep.4, 6255 (2014).
   PubMed Web of Science ®Google Scholar
• Barbareschi M , ButtittaF, FelicioniL, CotrupiS, BarassiF, DelGrammastro M. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin. Cancer Res.13(20), 6064–6069 (2007).
   PubMed Web of Science ®Google Scholar
• Mangone FR , BobrovnitchaiaIG, SalaorniS, ManuliE, NagaiMA. PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics (Sao Paulo)67(11), 1285–1290 (2012).
   PubMed Web of Science ®Google Scholar
• Yuan H , ChenJ, LiuY, OuyangT, LiJ, WangT. Association of PIK3CA mutation status before and after neoadjuvant chemotherapy with response to chemotherapy in women with breast cancer. Clin Cancer Res.21(19), 4365–4372 (2015).
   PubMed Web of Science ®Google Scholar
• Micalizzi DS , JuricD, NiemierkoA, ReynoldsKL, BorgerD, VoraSR. Abstract P1-13-03: association of PIK3CA mutation with clinical response to specific endocrine therapies in metastatic hormone receptor positive (HR+) breast cancer. Cancer Res.75(Suppl. 9), Abstract nr P1-13-03 (2015).
   Google Scholar
• Ramirez-Ardila DE , HelmijrJC, LookMP, LurkinI, Ruigrok-RitstierK, van LaereS. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res. Treat.139, 39–49 (2013).
   PubMed Web of Science ®Google Scholar
• Moynahan ME , ChenD, HeW, SungP, SamoilaA, YouD. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR +, HER2 − advanced breast cancer: results from BOLERO-2. Br. J. Cancer116, 726–730 (2017).
   PubMed Web of Science ®Google Scholar
• Sanchez CG , MaCX, CrowderRJ, GuintoliT, PhommalyC, GaoF. Preclinical modeling of combined phosphatidsylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res.13, R21 (2011).
   PubMed Web of Science ®Google Scholar
• Mosele F , StefanovskaB, LusqueA, TranDien A, GarberisI, DroinN. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann. Oncol.31(3), 377–386 (2020).
   PubMed Web of Science ®Google Scholar
• Krop IE , MayerIA, GanjuV, DicklerM, JohnstonS, MoralesS. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomized, double-blind, placebo-controlled, Phase II trial. Lancet17, 811–821 (2016).
   Google Scholar
• Baselga J , ImS-A, IwataH, CortesJ, DeLaurentiis M, JiangZ. Buparlisib plus fulvestrant versus placebo in postmenopausal, hormone receptor-positive, HER-2 negative, advanced breast cancer (BELLE-2): a randomized, double-blind, placebo-controlled, Phase III trial. Lancet18, 904–916 (2017).
   Web of Science ®Google Scholar
• Di Leo A , JohnstonS, LeeKS, CiruelosE, LonningPE, JanniW. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomized, double-blind, placebo-controlled Phase III trial. Lancet19, 87–100 (2018).
   Web of Science ®Google Scholar
• Fritsch C , HuangA, Chatenay-RivaudayC, SchnellC, ReddyA, LiuM. Characterization of the novel and specific PI3Ka inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther.13(5), 1117–1129 (2014).
   PubMed Web of Science ®Google Scholar
• Furet P , GuagnanoV, FairhurstRA, Imbach-WeeseP, BruceI, KnappM. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg. Med. Chem. Lett.23(13), 3741–3748 (2013).
   PubMed Web of Science ®Google Scholar
• Huang A , FritschC, WilsonC, ReddyA, LiuM, LeharJ. Abstract 3749: single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel. Cancer Res.72(Suppl. 8), Abstract nr 3749 (2012).
   Google Scholar
• Manna P , JainSK. PIP3 but not PIP2 increases GLUT4 surface expression and glucose metabolism mediated by AKT/PKCzeta/lambda phosphorylation in 3T3L1 adipocytes. Mol. Cell. Biochem.381(0), 291–299 (2013).
   PubMedGoogle Scholar
• Sano H , EguezL, TeruelMN, FukudaM, ChuangTD, ChavezJA. Rab10, a target of the AS160 Rab GAP, is required for insulin-stimulated translocation of GLUT4 to the adipocyte plasma membrane. Cell Metabolism5(4), 293–303 (2007).
   PubMed Web of Science ®Google Scholar
• Friedrichsen M , BirkJB, RichterEA, Ribel-MadsenR, PehmollerC, HansenBF. AKT2 influences glycogen synthase activity in human skeletal muscle through regulation of NH(2)-terminal (sites 2 + 2a) phosphorylation. Am. J. Physiol. Endocrinol. Metab.304(6), E631–E639 (2013).
   PubMed Web of Science ®Google Scholar
• Schnell CR , FerratT, WyssD, TinettoW, ToblerS, FritschC. Abstract 3933: circadian timing regimen for alpelisib (NVP-BYL719), a selective inhibitor of the class Ia PI3K isoform alpha to maximize therapeutic index. Cancer Res.78(Suppl. 13), Abstract nr 3933 (2018).
   Web of Science ®Google Scholar
• James A , BlumensteinL, GlaenzelU, JinY, DemaillyA, JakabA. Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers. Cancer Chemother. Pharmacol.76, 751–760 (2015).
   PubMed Web of Science ®Google Scholar
• Juric D , RodonJ, TaberneroJ, JankuF, BurrisHA, SchellensJHM. Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J. Clin. Oncol.36(13), 1291–1299 (2018).
   PubMed Web of Science ®Google Scholar
• De Buck SS , JakabA, BoehmM, BootleD, JuricD, QuadtC. Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies. Br. J. Clin. Pharmacol.78(3), 543–555 (2014).
   PubMed Web of Science ®Google Scholar
• Ando Y , IwasaS, TakahashiS, SakaH, KakizumeT, NatsumeK. Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci.110, 1021–1031 (2019).
   PubMed Web of Science ®Google Scholar
• Munster PN , HamiltonEP, EstevezLG, DeBoer RH, MayerIA, CamponeM. Phase IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2-breast cancer. J. Clin. Oncol.32(Suppl. 26), 143–143 (2014).
   Web of Science ®Google Scholar
• Juric D , JankuF, RodonJ, BurrisHA, MayerIA, SchulerM. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wildtype estrogen receptor-positive advanced breast cancer. A Phase Ib clinical trial. JAMA Oncol.5(2), e184475 (2018).
   Web of Science ®Google Scholar
• Nunnery SE , MayerIA. Management of toxicity to isoform α-specific PI3K inhibitors. Ann. Oncol.30(Suppl. 10), x21–x26 (2019).
   Google Scholar
• Liu Z , ZhuG, GetzenbergRH, VeltriRW. The upregulation of PI3K/Akt and MAP kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer. J. Cell. Biochem.116, 1341–1349 (2015).
   PubMed Web of Science ®Google Scholar
• Rodon J , CuriglianoG, DelordJ-P, HarbW, AzaroA, HanY. A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget9(60), 31709–31718 (2018).
   PubMedGoogle Scholar
• Vuylsteke P , HuizingM, PetrakovaK, RoylanceR, LaingR, ChanS. Pictilisib PIK3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER-2 negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicenter, placebo-controlled, Phase II randomized PEGGY study. Ann. Oncol.27, 2059–2066 (2016).
   PubMed Web of Science ®Google Scholar
• Martin M , ChanA, RirixL, O’ShaughnessyJ, HeggR, ManikhasA. A randomized adaptive Phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2 - advanced breast cancer (BELLE-4). Ann. Oncol.28, 313–320 (2017).
   PubMed Web of Science ®Google Scholar
• Sharma P , AbramsonVG, O’DeaA, LewisS, ScottJN, WardJ. Safety and efficacy results from Phase I study of BYL719 plus nab-paclitaxel in HER-2 negative metastatic breast cancer. Cancer Res.77(Suppl. 4), Abstract nr P6-11-08 (2017).
   Google Scholar
• Jain S , ShahAN, Santa-MariaCA, SiziopikouK, RademakerA, HelenowskiI. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast Cancer Res. Treat.171, 371–381 (2018).
   PubMed Web of Science ®Google Scholar
• Mayer IA , AbramsonVG, FormisanoL, BalkoJM, EstradaMV, SandersME. A Phase Ib study of alpelisib (BYL719), a PI3Kα-specific inhibitor, with letrozole in ER+/HER2− metastatic breast cancer. Clin. Cancer Res.23(1), 26–34 (2016).
   PubMed Web of Science ®Google Scholar
• Mayer IA , PratA, EgleD, BlauS, FidalgoJAP, GnantM. A Phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor positive, human epidermal growth factor receptor 2-negative breast cancer (NEO-ORB). Clin. Cancer Res.25(10), 2975–2987 (2019).
   PubMed Web of Science ®Google Scholar
• Ma CX , LuoJ, NaughtonM, AdemuyiwaF, SureshR, GriffithM. A Phase 1 trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer. Clin. Cancer Res.22(7), 1583–1591 (2016).
   PubMed Web of Science ®Google Scholar
• André F , CiruelosE, RubovskyG, CamponeM, LoiblS, RugoHS. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med.380(20), 1929–1940 (2019).
   PubMed Web of Science ®Google Scholar
• Franz MJ , BantleJP, BeebeCA, BrunzellJD, ChiassonJL, GargA. Nutrition principles and recommendations in diabetes. Diabetes Care27(Suppl. 1), S36 (2004).
   PubMedGoogle Scholar
• Busaidy NL , FarookiA, DowlatiA, PerentesisJP, DanceyJE, DoyleLA. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR Pathway. J. Clin. Oncol.30, 2919–2928 (2012).
   PubMed Web of Science ®Google Scholar
• Hopkins BD , PauliC, DuX, WangDG, LiX, WuD. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature560(7719), 499–503 (2018).
   PubMed Web of Science ®Google Scholar
• Calautti E , LiJ, SaoncellaS, BrissetteJL, GoetinckPF. Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death. J. Biol. Chem.280(38), 32856–32865 (2005).
   PubMed Web of Science ®Google Scholar
• Dickler MN , SauraC, RichardsDA, KropIE, CervantesA, BedardPL. Phase II study of Taselisib (GDC-0032) in combination with fulvestrant in patients with HER-2 negative, hormone-receptor positive advanced breast cancer. Clin. Cancer Res.24(18), 4380–4387 (2018).
   PubMed Web of Science ®Google Scholar
• Greenwell IB , IpA, CohenJB. PI3K inhibitors: understanding toxicity mechanisms and management. Oncology (Williston Park)31(11), 821–828 (2017).
   PubMed Web of Science ®Google Scholar
• Benson AB , AjaniJA, CatalanoRB, EngelkingC, KornblauSM, MartensonJA. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J. Clin. Oncol.22, 2918–2926 (2004).
   PubMed Web of Science ®Google Scholar
• Cheson BD , O’BrienS, EwerMS, GoncalvesMD, FarookiA, LenzG. Optimal management of adverse events from copanlisib in the treatment of patients with Non-Hodgkin lymphomas. Clin. Lymphoma, Myeloma Leuk.19(3), 135–141 (2019).
   PubMed Web of Science ®Google Scholar
• Laurent P-A , HechlerB, SolinhacR, RagabA, CabouC, AnquetilT. Impact of PI3Kα (phosphoinositide 3-kinase alpha) inhibition on hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol.38(9), 2041–2053 (2018).
   PubMed Web of Science ®Google Scholar
• Yang T , MeoliDF, MoslehiJ, RodenDM. Inhibition of the α-subunit of phosphoinositide 3-kinase in heart increases late sodium current and is arrhythmogenic. J. Pharmacol. Exp. Ther.365(3), 460–466 (2018).
   PubMed Web of Science ®Google Scholar
• Huw LY , O’BrienC, PanditaA, MohanS, SpoerkeJM, LuS. Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. Oncogenesis2(e83), 1–7 (2013).
   Google Scholar
• Nakanishi Y , WalterK, SpoerkeJM, O’BrienC, HuwLY, HamptonGM. Activating mutations in PIK3CB confer resistance to PI3K inhibition and define a novel oncogenic role for p110β. Cancer Res.76(5), 1193–1203 (2016).
   PubMed Web of Science ®Google Scholar
• Juric D , CastelP, GriffithM, GriffithOL, WonHH, EllisHet al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Ka inhibitor. Nature518(7538), 240–244 (2015).
   PubMed Web of Science ®Google Scholar
• Costa C , EbiH, MartiniM, BeausoleilSA, FaberAC, JakubikCT. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell.27(1), 97–108 (2015).
   PubMed Web of Science ®Google Scholar
• Schwartz S , WongvipatJ, TrigwellCB, HancoxU, CarverBS, Rodrik-OutmezguineV. Feedback suppression of PI3Kα signaling in PTEN mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell27(1), 109–122 (2015).
   PubMed Web of Science ®Google Scholar
• Razavi P , DicklerMN, ShahPD, ToyW, BrownDN, WonHH. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat. Cancer.1, 382–393 (2020).
   PubMedGoogle Scholar
• Elkabets M , VoraS, JuricD, MorseN, Mino-KenudsonM, MuranenT. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med.5(196), 196ra99 (2013).
   PubMed Web of Science ®Google Scholar
• Baselga J , CuriglianoG, MartínM, AndréF, BeckJT, TortoraG. Abstract CT061: a Phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2−breast cancer. Cancer Res.76(Suppl. 14), (2016).
   PubMedGoogle Scholar
• Varghese AM , MooreKN, HamiltonEP, HymanDM, JhaveriKL, WangXA. Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer patients. J. Clin. Oncol.35(Suppl. 15), 1064–1064 (2017).
   Google Scholar
• Radovich M , SolzakJP, HancockBA, StornioloAMV, SchneiderBP, MillerKD. Abstract OT3-06-02: an initial safety study of gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer. Cancer Res.79(Suppl. 4), (2019).
   Web of Science ®Google Scholar
• Britschgi A , AndraosR, BrinkhausH, KlebbaI, RomanetV, MuellerU. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell.22, 796–811 (2012).
   PubMed Web of Science ®Google Scholar
• Dey N , Leyland-JonesB, DeP. MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers. Am. J. Cancer Res.5(1), 1–19 (2015).
   PubMed Web of Science ®Google Scholar
• Le X , AntonyR, RazaviP, TreacyDJ, LuoF, GhandiM. Systematic functional characterization of resistance to PI3K inhibition in breast cancer. Cancer Discov.6(10), 1134–1147 (2016).
   PubMed Web of Science ®Google Scholar
• Serra V , EichhornPJ, García-GarcíaC, IbrahimYH, PrudkinL, SánchezG. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J. Clin. Invest.123(6), 2551–2563 (2013).
   PubMed Web of Science ®Google Scholar
• Durrant ST , NaglerA, GuglielmelliP, LavieD, le CoutreP, GisslingerH. Results from HARMONY: an open-label, multicenter, 2-arm, Phase Ib, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica104(12), e551–e554 (2019).
   PubMed Web of Science ®Google Scholar
• Cortes J , TamuraK, DeAngeloDJ, de BonoJ, LorenteD, MindenM. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br. J. Cancer118, 1425–1433 (2018).
   PubMed Web of Science ®Google Scholar
• Averous J , FonsecaBD, ProudCG. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene27(8), 1106–1113 (2008).
   PubMed Web of Science ®Google Scholar
• Vora SR , JuricD, KimN, Mino-KenudsonM, HuynhT, CostaCet al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell.26(1), 136–149 (2014).
   PubMed Web of Science ®Google Scholar
• Rehman FL , LordCJ, AshworthA. The promise of combining inhibition of PI3K and PARP as cancer therapy. Cancer Discov.2(11), 982–984 (2012).
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA , BarryWT, BirrerM, WestinSN, CadooKA, ShapiroGI. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion Phase Ib trial. Lancet20(4), 570–580 (2019).
   Web of Science ®Google Scholar
• Brandao M , CaparicaR, EigerD, de AzambujaE. Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Ann. Oncol.30(Suppl. 10), x27–x42 (2019).
   PubMedGoogle Scholar
• Chakrabarty A , SánchezV, KubaMG, RinehartC, ArteagaCL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. PNAS8(109), 2718–2723 (2012).
   Google Scholar
• Serra V , ScaltritiM, PrudkinL, EichhornPJA, IbrahimYH, ChandarlapatyS. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene30, 2547–2557 (2011).
   PubMed Web of Science ®Google Scholar
• Filho OM , GoelS, BarryWT, HamiltonEP, TolaneySM, YardleyDA. A mouse-human Phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC). J. Clin. Oncol.35(Suppl. 15), 1030–1030 (2017).
   Google Scholar
• Keegan NM , WalsheJM, ToomeyS, GulloG, KennedyMJ, BulgerKN. A Phase Ib trial of copanlisib and trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”. J. Clin. Oncol.36(Suppl. 15), 1036–1036 (2018).
   Web of Science ®Google Scholar
• Coussy F , BottyRE, LavigneM, GuC, FuhrmannL, BriauxA. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. J. Hematol. Oncol.13(13), 1–10 (2020).
   PubMedGoogle Scholar
• Banerji U , SmithAD, ZiviA, LorenteD, RihawiK, TunariuN. Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719. J. Clin. Oncol.32(Suppl. 15), 13559–13559 (2014).
   Web of Science ®Google Scholar
• Wheler JJ , AtkinsJT, JankuF, MoulderSL, StephensPJ, YelenskyR. Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience3(5–6), 164–172 (2016).
   PubMedGoogle Scholar
• Hyman DM , TranB, JaimeJC, GarraldaE, MachielsJ-PH, SchellensJHM. Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors. J. Clin. Oncol.34(Suppl. 15), 2500–2500 (2016).
   Google Scholar
• Usman MW , GaoJ, ZhengT, RuiC, LiT, BianX. Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling. Cell Death Disease.9(809), 1–12 (2018).
   PubMedGoogle Scholar
• Ali K , SoondDR, PineiroR, HagemannT, PearceW, LimEL. Inactivation of the PI3K p110δ breaks regulatory T cell-mediated immune tolerance to cancer. Nature510(7505), 407–411 (2014).
   PubMed Web of Science ®Google Scholar
• Schmid MC , AvraamidesCJ, DippoldHC, FrancoI, FoubertP, ElliesLG. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3Kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell.19(6), 715–727 (2011).
   PubMed Web of Science ®Google Scholar
• Fokas E , ImJH, HillS, XameenS, StratfordM, BeechJ. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res.72(1), 239–248 (2012).
   PubMed Web of Science ®Google Scholar
• Cretella D , DigiacomoG, GiovanettiE, CavazonniA. PTEN alterations as a potential mechanism for tumor cell escape from PD-1/PD-L1 inhibition. Cancers11(1318), 1–17 (2019).
   Google Scholar
• Sun C , MezzadraR, SchumacherTN. Regulation and function of the PD-L1 checkpoint. Immunity48, 434–452 (2018).
   PubMed Web of Science ®Google Scholar
• Sai J , OwensP, NovitskiySV, HawkinsOE, VilgelmAE, YangJ. PI3K inhibition reduces mammary tumor growth and facilitates anti-tumor immunity and anti-PD1 responses. Clin. Cancer Res.23(13), 3371–3384 (2017).
   PubMed Web of Science ®Google Scholar
• Baselga J , DentSF, CortésJ, ImY-H, DiérasV, HarbeckN. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): primary analysis from SANDPIPER. J. Clin. Oncol.36(Suppl. 18), 1006–1006 (2018).
   Web of Science ®Google Scholar
• Rugo HS , BianchiGV, ChiaSKL, TurnerNC, JuricD, JacotW. BYLieve: a Phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy. J. Clin. Oncol.36(Suppl. 15), TPS1107–TPS1107 (2018).
   Web of Science ®Google Scholar
• Rugo HS , LereboursF, CiruelosE, DrullinskyP, BorregoMR, NevenP. Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. J. Clin. Oncol.38(Suppl; abstr 1006), (2020).
   Google Scholar
• Vernieri C , CortiF, NichettiF, LigorioF, ManglavitiS, ZattarinE. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of /AKT/mTORC1 pathway with different clinical implications. Breast Cancer Res.22(33), 1–13 (2020).
   Google Scholar